MÆDICA - a Journal of Clinical Medicine Logo
  • Home
  • Profile
  • Standards
    • Types of articles
    • Instructions for authors
    • Editing rules (peer-review protocol)
    • Official Journal’s protocols
  • Editorial Council
  • Peer-review TEAM
  • How to
  • Menu

Author archives

  • About
  • Latest Posts

Alireza ABDOLLAHI

Department of Pathology, Imam Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran

Latest posts by Alireza ABDOLLAHI (see all)

  • Is Serum Prostate-specific Antigen a Diagnostic Marker for Benign and Malignant Breast Tumors in Women? - June 30, 2015

Articles signed on MÆDICA, JCM:

Is Serum Prostate-specific Antigen a Diagnostic Marker for Benign and Malignant Breast Tumors in Women?

SELECT ISSUE

MÆDICA - a Journal of Clinical Medicine | Vol. 10, nr. 2, 2015

CNCSIS - CMR - B+ OBBCSSR

HIGHLIGHTS

What is plagiarism

Plagiarism’s meaning comes from the Latin word ‘plagiarius,’ which means to kidnap. When someone uses the work of another writer or artist without properly citing the source or giving credit, that’s plagiarism. [...]

Committe on Publication Ethics

A forum for responsible and ethical research publishing – Code of Conduct and Best Practice Guidelines for Journal Editors.

Members Area


Is Serum Prostate-specific Antigen a Diagnostic Marker for Benign and Malignant Breast Tumors in Women?

Seyed Hasan Emami RAZAVI, Mahsa GHAJARZADEH, Alireza ABDOLLAHI, Saeed SHOAR and Ramesh OMRANIPOUR

ABSTRACT

Background: Breast cancer is the most common cancer in women. Prostrate-specific antigen (PSA) is a marker of prostate gland malignancy which has been considered in cases with breast cancer in recent years. The goal of this study was to determine total and free PSA levels in cases with malignant and benign breast lesions.

Method: Ninety women with histological proved malignant breast masses and 90 with benign breast masses were enrolled. Total and free PSA levels along with histological grade and conditions of vascular and perinural invasion, status of hormonal tumor receptors, immune-histo-chemistry markers recorded for all cases. Total and free PSA levels were assessed after treatment in cases with malignant masses.

Results: Total and free PSA levels were significantly higher in cases with malignant masses. The best cut off point for total PSA to differentiate benign and malignant masses was 0.31 and the best cut off point for free PSA to differentiate benign and malignant masses was 0.19. After treatment, mean free PSA level was significantly lower than free PSA before treatment (0.23 vs 0.3, p<0.001).

Conclusion: serum PSA level could be applied for differentiating benign and malignant breast masses.

Keywords: PSA, breast, diagnosis

Full text | PDF



plic-mail[email protected]

 Terms and conditions

© MÆDICA - a Journal of Clinical Medicine - All rights reserved